| Project/Area Number |
20591588
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
ISHIZONE Satoshi Shinshu University, 医学部附属病院, 助教 (90419341)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAGAWA Shinichi 信州大学, 医学部, 教授 (80229806)
KOMATSU Daisuke 信州大学, 医学部附属病院, 助教 (50507481)
MURANAKA Futoshi 信州大学, 医学部附属病院, 医員 (80507492)
|
|---|
| Research Collaborator |
SHIMIZU Akira 信州大学, 医学部附属病院, 助教 (00447773)
KITAHARA Hiroe 信州大学, 医学部附属病院, 医員 (20569321)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | バイオパンニング法 / 消化器癌標的治療 / ペプチド / バイオパニング法 |
|---|
| Research Abstract |
Cholangiocarcinoma (CCA) is a common carcinoma of the liver, and the majority of patients with CCA have a poor prognosis due to the lack of effective non-surgical therapies in addition to its rapid progression and inoperability at the time of diagnosis. The development of novel non-surgical therapeutics that efficiently target CCA could significantly improve the prognosis for patients presenting with CCA. Here, we describe the iteration and characterization of a novel peptide, designated COP35 (CCA-binding oligo-peptide #35) that binds selectively to human CCA identified by bacteriophage biopanning using the intrahepatic cholangiocarcinoma cell line RBE and the normal cholangiocyte cell line MMNK-1. COP35 was found to augment the growth inhibitory effects of 5-FU against RBE cells. Utilizing pull down assay and liquid chromatography, we identify the clathrin heavy chain (CHC) accompanied by GRP78/BiP as a COP35 binding partner. In summary, we identify COP35 as a possible candidate for peptide targeted therapies for CCA.
|
